First allo T cell gets European nod

Ebvallo works by targeting and eliminating EBV-infected cells in immunocompromised patients who lack sufficient T cells to combat the virus. The company’s allogeneic platform consists of T cells enriched from whole blood from third-party donors, activated through exposure to certain viral antigens, and stored for later use in a partially human leukocyte antigen (HLA)-matched patient. The company expects to leverage this technology to treat other cancers and autoimmune diseases. One of its allogeneic EBV T cell treatments, ATA188, is in a phase 2 study to treat progressive forms of multiple sclerosis. This investigational off-the-shelf immunotherapy has the potential to selectively identify and tackle EBV-infected B and plasma cells in the nervous system that are associated with the demyelinating disease.

留言 (0)

沒有登入
gif